CS-1008 + FOLFIRI
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
May 1, 2010 → Aug 1, 2013
NCT ID
NCT01124630About CS-1008 + FOLFIRI
CS-1008 + FOLFIRI is a phase 1 stage product being developed by Daiichi Sankyo for Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01124630. Target conditions include Metastatic Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01124630 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Colorectal Cancer